MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ
25.07
-0.57
-2.22%
After Hours: 25.07 0 0.00% 17:22 12/30 EST
OPEN
25.49
PREV CLOSE
25.64
HIGH
25.99
LOW
24.97
VOLUME
708.30K
TURNOVER
--
52 WEEK HIGH
36.26
52 WEEK LOW
2.860
MARKET CAP
1.97B
P/E (TTM)
-13.8861
1D
5D
1M
3M
1Y
5Y
1D
Director Cyrus Harmon Reports Sale of Olema Pharmaceuticals Common Shares
Reuters · 20h ago
Weekly Report: what happened at OLMA last week (1222-1226)?
Weekly Report · 1d ago
Will Olema Pharmaceuticals’ (OLMA) Index Debut Quietly Redefine Its Standing Among Biotech Investors?
Simply Wall St · 5d ago
Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal
Seeking Alpha · 6d ago
Olema Pharmaceuticals Chief Discovery Officer David C. Myles Reports Disposal of Common Shares
Reuters · 6d ago
Olema Pharmaceuticals Chief Medical Officer Naseem Zojwalla Reports Disposal of Common Shares
Reuters · 6d ago
Olema Pharmaceuticals (OLMA): Reassessing Valuation After S&P Biotechnology Select Industry Index Inclusion
Simply Wall St · 12/23 03:25
Abivax is the top performing biotechnology stock YTD
Seeking Alpha · 12/22 21:07
More
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

Webull offers Olema Pharmaceuticals Inc stock information, including NASDAQ: OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.